Lupin set to launch brivaracetam in US after getting regulator's approval
This story was originally published at 20:15 IST on 24 February 2026
Register to read our real-time news.Informist, Tuesday, Feb. 24, 2026
--Lupin gets US FDA approval for brivaracetam oral solution
MUMBAI – Lupin Ltd. has begun the process to launch brivaracetam oral solution in the US after getting approval from the US Food and Drug Administration. The company has got the approval to sell the drug in strength of 10 milligrams per milliliter, Lupin said on Tuesday.
Brivaracetam is used to treat partial-onset seizures in patients older than one month. The drug had estimated sales of $135 million in the US in 2025, the company said.
For the December quarter, Lupin's consolidated net profit was INR 11.76 billion on revenue of INR 71.68 billion. Tuesday, shares of the company closed at INR 2,250.20 on the National Stock Exchange, up 0.4%. End
US$1 = INR 90.95
Reported by Anshul Choudhary
Edited by Akul Nishant Akhoury
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
